Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Key Slides
Question of the Week
Donate
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Fellow Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Menu
H. Nina Kim, MD, MS
H. Nina Kim, MD, MS
University of Washington
Seattle, WA
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Key Slides
Question of the Week
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Fellow Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Practice Question of the Week
January 20, 2025: Tirzepatide Dose and Weight Loss in a Person With HIV
A 52-year-old woman with HIV presents for routine follow-up care. She has an undetectable plasma HIV RNA level and currently takes aspirin 81 mg daily, rosuvastatin 20 mg daily, lisinopril 20 mg daily, and tirzepatide 10 mg weekly. Over the past 3 months, she has achieved 10% weight loss through a combination of lifestyle changes and medication support. Her current weight is 216 lb, with a body mass index of 34 kg/m2. Her last hemoglobin A1c level was 6.0%. She would like to achieve an additional 8% weight loss to reach a goal weight of 200 lb or lower. She experiences nausea after each weekly tirzepatide dose and has trouble eating 3 meals per day due to significant appetite suppression. Which of the following is the best response?
A. Increase dose of tirzepatide to 12.5 mg weekly
B. Start a combination of weight training and increased protein intake in her diet
C. Recommend bariatric surgery
D. Add metformin to her regimen
E. Something else
Register for the Webinar
View Archived Questions
Leave Feedback
Subscribe
CLOSE
